Research Compendium/SLU-PP-332
Performance ResearchResearch OnlyNot For Human Consumption

SLU-PP-332

ERR agonist · Exercise mimetic peptide · SLU-PP

ERR nuclear receptor agonist that activates the same gene pathways as aerobic exercise - studied as an endurance and metabolic mimetic.

MECHANISM OF ACTION

SLU-PP-332 is a small molecule agonist of ERRα, ERRβ, and ERRγ (estrogen-related receptors) - nuclear receptors that regulate mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation gene networks. Activation mimics the transcriptional response to prolonged aerobic exercise without physical activity. Research in rodent models demonstrates enhanced endurance, increased mitochondrial density in muscle, and improved metabolic parameters. Unlike traditional performance peptides, SLU-PP-332 works via nuclear receptor transcriptional activation rather than hormonal pathways.

RESEARCH APPLICATIONS

  • Exercise mimetic research - endurance and VO2 max modelling
  • Mitochondrial biogenesis upregulation
  • Fatty acid oxidation and metabolic efficiency
  • Heart failure and muscle wasting models
  • Combination with AMPK activators (MOTS-C)

RESEARCH HIGHLIGHTS

Endurance Enhancement in Mice

2023

SLU-PP-332 (4 weeks, 100mg/kg IP) increased running capacity by ~70% vs. controls and upregulated PGC-1α, VEGF, and oxidative metabolism genes in skeletal muscle.

Ref: Banerjee et al., J Med Chem

ERR Trifecta Agonism

2023

Structural studies confirm simultaneous agonism at ERRα, β, and γ - activating a broader transcriptional programme than selective ERR agonists.

Ref: Pourcet et al., Nat Chem Biol

RESEARCH PROTOCOL NOTES

Research doses100 mg/kg in rodent models; human research doses not established
RouteIP in animal studies; SC or oral in emerging protocols
Available formatsPen (1.2–2mg - Peptide Pen, Noventra)

Chemical Identity

CAS Number2099617-43-1

Storage & Stability

Small molecule - stable at 2–8°C. Protect from light. Less degradation-sensitive than peptides.

Regulatory Status

Very early-stage research compound. No clinical trials. Not WADA prohibited (not yet on radar). SA: unscheduled research compound.

Back to Research CompendiumView Research Compounds →